Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $144 from $146 and keeps an Equal Weight rating on the shares after the company posted a Q2 beat and raised 2025 revenue and EPS guidance. The firm updated its model for Q2 trends and commentary, while also rolling forward the discount period, resulting in its adjusted price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Litifilimab Study: A Long-Term Hope for Lupus Treatment
- Morning Movers: Roblox skyrockets following second quarter results
- Biogen’s Strong Performance and Positive Outlook Drive Buy Rating
- Biogen reports Q2 adjusted EPS $5.47, consensus $3.87
- Biogen raises FY25 adjusted EPS view to $15.50-$16.00 from $14.50-$15.50